Dopamine/Angiostensin Receptors in Genetic Hypertension

遗传性高血压中的多巴胺/血管紧张素受体

基本信息

  • 批准号:
    6704382
  • 负责人:
  • 金额:
    $ 198.71万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2004
  • 资助国家:
    美国
  • 起止时间:
    2004-04-01 至 2009-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Because the kidney is important in the long term regulation of blood pressure and is the major organ involved in the regulation of sodium homeostasis, many studies have focused on abnormal renal handling of sodium chloride in the pathogenesis of essential hypertension. The autocrine/paracrine agents, dopamine and angiotensin II, work in an opposing manner to regulate renal function. Specifically, dopamine, via dopamine D1 and D3 receptors, is natriuretic while angiotensin II, via AT1 receptors, is antinatriuretic. Increased activity of the renin angiotensin system (RAS) and loss of function in the dopaminergic system lead to sodium retention and hypertension. We have reported that impairment of the renal D1 receptor in mice caused by overexpressing the G protein-coupled receptor kinase type 4 variant, GRK4 A142V, leads to high blood pressure. A similar mechanism may be operating in human essential hypertension; the GRK4 gene locus (chromosome 4p16.3) is linked to and GRK4 variants are associated with hypertension. GRK4 variants impair D1 receptor function in human renal proximal tubules. Expression of GRK4 variants in cell lines replicates the D1 receptor defect noted in renal proximal tubules. Inhibition of GRK4 function or expression normalizes D11 receptor function in and human renal proximal tubule cells/cell lines expressing GRK4 gene variants. Moreover, renal selective prevention of the expression of GRK4 in spontaneously hypertensive rats attenuates the development of hypertension. The overall goal of this PPG is to test the hypothesis that in genetic hypertension the reduction of D1 and D3 receptor function, caused by GRK4, cannot oppose AT1 receptor function leading to increased renal sodium reabsorption and high blood pressure. To accomplish our goal, we have organized a team of investigators, experienced in studies of dopamine and RAS, to elucidate the nature of their gene/gene interactions in health and in hypertension. Project by Felder will test the hypothesis that variant GRK4 proteins have increased constitutive activities that desensitize the D1 receptor but not the AT1 receptor. Project by Carey will test the hypothesis that salt sensitivity is produced when GRK4 variants desensitize the D1 receptor in the kidney, and that hypertension is produced when variants related to the RAS are also present. Project by Jose will test the hypothesis that renal proximal tubule sodium transport is regulated, in part, by an interaction among D1, D3, and AT1 receptors and that an aberrant interaction occurs in hypertension because of GRK4 variants. These gene/gene interactions are in keeping with the critical roles these receptors play in the polygenic causation of genetic hypertension.
描述(由申请人提供): 由于肾脏在血压的长期调节中是重要的,并且是参与钠稳态调节的主要器官,因此许多研究集中在原发性高血压发病机制中的肾脏对氯化钠的异常处理。 自分泌/旁分泌剂多巴胺和血管紧张素II以相反的方式调节肾功能。 具体来说,多巴胺通过多巴胺D1和D3受体是利钠的,而血管紧张素II通过AT 1受体是抗心房利尿的。 肾素血管紧张素系统(RAS)活性增加和多巴胺能系统功能丧失导致钠潴留和高血压。 我们已经报道过,在小鼠中,由于过度表达G蛋白偶联受体激酶4型变体GRK 4 A142 V而导致肾D1受体受损,从而导致高血压。 类似的机制可能在人类原发性高血压中起作用; GRK 4基因位点(染色体4p16.3)与高血压相关,GRK 4变体与高血压相关。 GRK 4变体损害人肾近端小管中的D1受体功能。 GRK 4变体在细胞系中的表达复制了肾近端小管中注意到的D1受体缺陷。 GRK 4功能或表达的抑制使表达GRK 4基因变体的人肾近端小管细胞/细胞系中的D11受体功能正常化。 此外,肾脏选择性地抑制自发性高血压大鼠GRK 4的表达可减轻高血压的发展。 本PPG的总体目标是检验以下假设:在遗传性高血压中,GRK 4引起的D1和D3受体功能降低不能对抗AT 1受体功能,导致肾钠重吸收增加和高血压。 为了实现我们的目标,我们组织了一个研究小组,在多巴胺和RAS的研究经验,阐明他们的基因/基因在健康和高血压的相互作用的性质。 Felder的项目将测试变体GRK 4蛋白具有增加的组成性活性的假设,所述组成性活性使D1受体而不是AT 1受体脱敏。 Carey的项目将测试以下假设:当GRK 4变体使肾脏中的D1受体脱敏时产生盐敏感性,并且当与RAS相关的变体也存在时产生高血压。 Jose的项目将检验肾近端小管钠转运部分受D1、D3和AT 1受体之间相互作用调节的假设,以及GRK 4变体导致高血压发生异常相互作用的假设。 这些基因/基因相互作用与这些受体在遗传性高血压的多基因病因中发挥的关键作用一致。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robin A Felder其他文献

Effects of Decreased Renal Cortical Expression of G Protein—Coupled Receptor Kinase 4 and Angitensin Type 1 Receptors in Rats
  • DOI:
    10.1291/hypres.31.1455
  • 发表时间:
    2008-07-01
  • 期刊:
  • 影响因子:
    4.600
  • 作者:
    Junichi Yatabe;Hironobu Sanada;Sanae Midorikawa;Shigeatsu Hashimoto;Tsuyoshi Watanabe;Peter M Andrews;Ines Armando;Xiaoyan Wang;Robin A Felder;Pedro A Jose
  • 通讯作者:
    Pedro A Jose
DOPAMINE D1A RECEPTOR REGULATION OF PHOSPHOLIPASE C (PLC) ISOFORM EXPRESSION. • 2219
  • DOI:
    10.1203/00006450-199604001-02244
  • 发表时间:
    1996-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Pei-Ying Yu;Gilbert M Eisner;Ikuyo Yamaguchi;M. Maral Mouradian;Robin A Felder;Pedro A Jose
  • 通讯作者:
    Pedro A Jose
1592 FUNCTION OF RENAL DOPAMINE-2 RECEPTORS
  • DOI:
    10.1203/00006450-198504000-01616
  • 发表时间:
    1985-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Christian C Felder;Robin A Felder;Robert R Holloway;Jean E Robillard;Pedro A Jose
  • 通讯作者:
    Pedro A Jose
Mechanisms of Disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity
疾病机制:GRK4 在原发性高血压和盐敏感性病因学中的作用
  • DOI:
    10.1038/ncpneph0301
  • 发表时间:
    2006-11-01
  • 期刊:
  • 影响因子:
    39.800
  • 作者:
    Robin A Felder;Pedro A Jose
  • 通讯作者:
    Pedro A Jose
DOPAMINE RECEPTORS (DR) IN DOG INTRARENAL ARTERIES(IRA)
  • DOI:
    10.1203/00006450-198404001-01607
  • 发表时间:
    1984-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Robin A Felder;John J Worthington;Pedro A Jose
  • 通讯作者:
    Pedro A Jose

Robin A Felder的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robin A Felder', 18)}}的其他基金

VALIDATION AND IN-HOME ASSESSMENT OF THE NAPS SYSTEM
NAPS 系统的验证和家庭评估
  • 批准号:
    7718570
  • 财政年份:
    2008
  • 资助金额:
    $ 198.71万
  • 项目类别:
Pressure Ulcer Detection in Darkly Pigmented Skin
深色皮肤压疮检测
  • 批准号:
    7270197
  • 财政年份:
    2007
  • 资助金额:
    $ 198.71万
  • 项目类别:
In-Home Monitoring of Selected Independent ADLs
选定的独立 ADL 的家庭监控
  • 批准号:
    6736594
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopamine/Angiostensin Receptors in Genetic Hypertension
遗传性高血压中的多巴胺/血管紧张素受体
  • 批准号:
    7413375
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopaminergic and angiotensin regulation of sodium metabolism via the sodium bicarbonate co-transporter (SLC4A5) in the human renal proximal and distal tubule cells: Role of GRK4 on salt sensitivity
多巴胺能和血管紧张素通过碳酸氢钠协同转运蛋白 (SLC4A5) 在人肾近端和远端小管细胞中调节钠代谢:GRK4 对盐敏感性的作用
  • 批准号:
    9283598
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
High Productivity Eukaryotic Cell Culture Technology
高产真核细胞培养技术
  • 批准号:
    6833399
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopamine and Angiotensin Receptor Interactions in Genetic Hypertension
遗传性高血压中多巴胺和血管紧张素受体的相互作用
  • 批准号:
    7938789
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopamine/Angiostensin Receptors in Genetic Hypertension
遗传性高血压中的多巴胺/血管紧张素受体
  • 批准号:
    7219435
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopamine and Angiotensin Receptor Interactions in Genetic Hypertension
遗传性高血压中多巴胺和血管紧张素受体的相互作用
  • 批准号:
    7764188
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:
Dopamine/Angiostensin Receptors in Genetic Hypertension
遗传性高血压中的多巴胺/血管紧张素受体
  • 批准号:
    6871351
  • 财政年份:
    2004
  • 资助金额:
    $ 198.71万
  • 项目类别:

相似海外基金

Exploratory Efficacy-Evaluation Study of Angiotensin Receptor-Neprilysin Inhibitor in patients with dialysis
血管紧张素受体脑啡肽酶抑制剂在透析患者中​​的探索性疗效评价研究
  • 批准号:
    21K16191
  • 财政年份:
    2021
  • 资助金额:
    $ 198.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Personalizing Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy in Chronic Kidney Disease
慢性肾脏病的个体化血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗
  • 批准号:
    10313873
  • 财政年份:
    2021
  • 资助金额:
    $ 198.71万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10469311
  • 财政年份:
    2020
  • 资助金额:
    $ 198.71万
  • 项目类别:
Impact of an Angiotensin Receptor Blocker in Aortic Stenosis - a Randomized Controlled Trial
血管紧张素受体阻滞剂对主动脉瓣狭窄的影响 - 一项随机对照试验
  • 批准号:
    433568
  • 财政年份:
    2020
  • 资助金额:
    $ 198.71万
  • 项目类别:
    Operating Grants
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10649490
  • 财政年份:
    2020
  • 资助金额:
    $ 198.71万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10210299
  • 财政年份:
    2020
  • 资助金额:
    $ 198.71万
  • 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
  • 批准号:
    10065083
  • 财政年份:
    2020
  • 资助金额:
    $ 198.71万
  • 项目类别:
Mechanism of suppressive effects for atherosclerosis by Angiotensin Receptor-Neprilysin Inhibitor
血管紧张素受体脑啡肽酶抑制剂抑制动脉粥样硬化的机制
  • 批准号:
    19K17618
  • 财政年份:
    2019
  • 资助金额:
    $ 198.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Pathophysiological significance of angiotensin receptor-binding protein in leucocytes and immune cells
白细胞和免疫细胞中血管紧张素受体结合蛋白的病理生理意义
  • 批准号:
    19K17575
  • 财政年份:
    2019
  • 资助金额:
    $ 198.71万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Angiotensin receptor G protein signal switching in AgRP neurons in cardiometabolic control
AgRP 神经元中血管紧张素受体 G 蛋白信号转换在心脏代谢控制中的作用
  • 批准号:
    10658260
  • 财政年份:
    2017
  • 资助金额:
    $ 198.71万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了